These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
288 related items for PubMed ID: 32735324
1. Glycogen Synthase Kinase-3β Mediates Proinflammatory Cytokine Secretion and Adipogenesis in Orbital Fibroblasts from Patients with Graves' Orbitopathy. Lee JS, Chae MK, Kikkawa DO, Lee EJ, Yoon JS. Invest Ophthalmol Vis Sci; 2020 Jul 01; 61(8):51. PubMed ID: 32735324 [Abstract] [Full Text] [Related]
2. Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves' Orbitopathy in Orbital Fibroblasts. Lee GE, Kim J, Lee JS, Ko J, Lee EJ, Yoon JS. Front Endocrinol (Lausanne); 2020 Jul 01; 11():607144. PubMed ID: 33488522 [Abstract] [Full Text] [Related]
5. Therapeutic Effect of Guggulsterone in Primary Cultured Orbital Fibroblasts Obtained From Patients with Graves' Orbitopathy. Kim BR, Kim J, Lee JE, Lee EJ, Yoon JS. Invest Ophthalmol Vis Sci; 2020 Mar 09; 61(3):39. PubMed ID: 32196098 [Abstract] [Full Text] [Related]
7. Biguanides Metformin and Phenformin Generate Therapeutic Effects via AMP-Activated Protein Kinase/Extracellular-Regulated Kinase Pathways in an In Vitro Model of Graves' Orbitopathy. Han YE, Hwang S, Kim JH, Byun JW, Yoon JS, Lee EJ. Thyroid; 2018 Apr 09; 28(4):528-536. PubMed ID: 29589999 [Abstract] [Full Text] [Related]
9. Pentraxin 3 mediates inflammation and adipogenesis in Graves' orbitopathy pathogenesis. Kim MS, Park HY, Choi SH, Chang EJ, Ko J, Yoon JS. J Mol Endocrinol; 2024 Nov 01; 73(4):. PubMed ID: 39283923 [Abstract] [Full Text] [Related]
10. The Role of Adipsin, Complement Factor D, in the Pathogenesis of Graves' Orbitopathy. Byeon HJ, Chae MK, Ko J, Lee EJ, Kikkawa DO, Jang SY, Yoon JS. Invest Ophthalmol Vis Sci; 2023 Aug 01; 64(11):13. PubMed ID: 37555734 [Abstract] [Full Text] [Related]
11. The Role of Sphingosine-1-Phosphate in Adipogenesis of Graves' Orbitopathy. Kim SE, Lee JH, Chae MK, Lee EJ, Yoon JS. Invest Ophthalmol Vis Sci; 2016 Feb 01; 57(2):301-11. PubMed ID: 26830367 [Abstract] [Full Text] [Related]
14. PERK mediates oxidative stress and adipogenesis in Graves' orbitopathy pathogenesis. Ko J, Kim JY, Kyoung Chae M, Jig Lee E, Sook Yoon J. J Mol Endocrinol; 2021 May 11; 66(4):313-323. PubMed ID: 33870911 [Abstract] [Full Text] [Related]
15. Anti-oxidative and anti-adipogenic effects of caffeine in an in vitro model of Graves' orbitopathy. Ko J, Kim JY, Kim JW, Yoon JS. Endocr J; 2020 Apr 28; 67(4):439-447. PubMed ID: 31941844 [Abstract] [Full Text] [Related]
18. Phospholipase C-γ as a Potential Therapeutic Target for Graves' Orbitopathy. Roh TH, Chae MK, Ko JS, Kikkawa DO, Jang SY, Yoon JS. Endocrinol Metab (Seoul); 2023 Dec 28; 38(6):739-749. PubMed ID: 37989267 [Abstract] [Full Text] [Related]
19. Platelet-derived growth factor-BB: a stimulus for cytokine production by orbital fibroblasts in Graves' ophthalmopathy. van Steensel L, Paridaens D, Dingjan GM, van Daele PL, van Hagen PM, Kuijpers RW, van den Bosch WA, Drexhage HA, Hooijkaas H, Dik WA. Invest Ophthalmol Vis Sci; 2010 Feb 28; 51(2):1002-7. PubMed ID: 19797221 [Abstract] [Full Text] [Related]
20. Melatonin attenuated adipogenesis through reduction of the CCAAT/enhancer binding protein beta by regulating the glycogen synthase 3 beta in human mesenchymal stem cells. Rhee YH, Ahn JC. J Physiol Biochem; 2016 Jun 28; 72(2):145-55. PubMed ID: 26797706 [Abstract] [Full Text] [Related] Page: [Next] [New Search]